One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
IDEXX Laboratories logo
IDEXX Laboratories IDXX
$ 675.24 -2.1%
report update icon

Quarterly report 2026-Q3
added 11-02-2026

IDEXX Laboratories Financial Statements 2025-2007 | IDXX

Annual Financial Statements IDEXX Laboratories

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007

Market Cap

51.1 B 37.7 B 47.4 B 42.8 B 45.4 B 44.4 B 24.4 B 18 B 16.4 B 10.8 B 6.5 B 7.93 B 6.05 B 5.29 B 4.81 B 1.8 B 1.29 B 1.5 B -

Shares

80.4 M 82.5 M 83.1 M 83.6 M 85.2 M 85.3 M 86.1 M 86.9 M 87.8 M 89.7 M 92.6 M 100 M 106 M 110 M 114 M 57.7 M 58.8 M 60 M -

Historical Prices

636 457 571 511 532 520 255 211 187 145 73.2 78.4 63 46.1 42.9 31.2 21.9 25 22.2

Net Income

1.06 B 888 M 845 M 679 M 745 M 582 M 428 M 377 M 263 M 222 M 192 M 182 M 188 M 178 M 162 M 141 M 122 M 116 M -

Revenue

4.3 B 3.9 B 3.66 B 3.37 B 3.22 B 2.71 B 2.41 B 2.21 B 1.97 B 1.78 B 1.6 B 1.49 B 1.38 B 1.29 B 1.22 B - - - -

Cost of Revenue

1.64 B 1.52 B 1.47 B 1.36 B 1.33 B 1.14 B 1.04 B 972 M 872 M 800 M 712 M 670 M 621 M 594 M 572 M 525 M 505 M 494 M -

Gross Profit

2.66 B 2.38 B 2.19 B 2 B 1.89 B 1.57 B 1.37 B 1.24 B 1.1 B 975 M 890 M 816 M 756 M 699 M 647 M 579 M 526 M 530 M -

Operating Income

1.36 B 1.13 B 1.1 B 899 M 932 M 695 M 553 M 491 M 413 M 350 M 300 M 260 M 267 M 263 M 236 M 204 M 176 M 172 M -

Interest Expense

- - 41.6 M 39.9 M 29.8 M 33.1 M 31.1 M 34.7 M 37.2 M 32 M 29.2 M 15.4 M 5.39 M 3.85 M 3.55 M 2.42 M 1.92 M 4.59 M -

EBITDA

1.51 B 1.26 B 1.21 B 1.01 B 1.04 B 791 M 641 M 575 M 496 M 428 M 377 M 319 M 321 M 315 M 284 M 250 M 226 M 220 M -

Operating Expenses

1.3 B 1.25 B 1.09 B 1.11 B 957 M 877 M 813 M 750 M 684 M 625 M 582 M 556 M 489 M 437 M 410 M 375 M 350 M 357 M -

General and Administrative Expenses

405 M 442 M 336 M 326 M 310 M 301 M 261 M 245 M 221 M 207 M 183 M 174 M 158 M 138 M 129 M 127 M 117 M 117 M -

All numbers in USD currency

Quarterly Income Statement IDEXX Laboratories

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1 2010-Q4 2010-Q3 2010-Q2

Shares

78.8 M 79 M 79.6 M -178 K 80.1 M 80.4 M 81.3 M -208 K 82.3 M 82.6 M 83.1 M 8 K 83.1 M 83.1 M 83 M -232 K 83.2 M 83.9 M 84.4 M -125 K 85.1 M 85.3 M 85.5 M 49 M 85.3 M 85.1 M 85.4 M -91 K 86.2 M 86.2 M 86.2 M 86.1 M 86.8 M 87 M 87.3 M -115 K 87.5 M 88 M 88.1 M -149 K 89.9 M 89.8 M 89.9 M -593 K 91.9 M 93.4 M 94.3 M -1.55 M 99.5 M 102 M 51.6 M 52.8 M 52.4 M 53.7 M 54.6 M -89 K 54.9 M 55.1 M 55.2 M -351 K 56.7 M 57.3 M 57.5 M -86 K 57.6 M 57.7 M

Net Income

317 M 338 M 278 M 248 M 275 M 294 M 243 M 216 M 233 M 203 M 236 M 195 M 212 M 224 M 214 M 172 M 181 M 132 M 194 M 163 M 175 M 203 M 204 M 175 M 146 M 149 M 112 M 90.5 M 109 M 126 M 103 M 85.6 M 93.3 M 109 M 89.5 M 38.3 M 70.5 M 85.4 M 69.1 M 52.4 M 56.5 M 67.2 M 46 M 44.3 M 44.2 M 56.9 M 46.6 M 26 M 52.2 M 57.2 M 46.6 M 43.3 M 45.7 M 54 M 44.9 M 43.4 M 42.9 M 51.3 M 40.7 M 38 M 38.5 M 48.7 M 36.6 M 36.4 M 34.7 M 37.2 M

Revenue

1.21 B 1.22 B 1.14 B 1.09 B 1.11 B 1.11 B 998 M 954 M 976 M 1 B 964 M 902 M 916 M 944 M 900 M 829 M 842 M 861 M 837 M 801 M 810 M 826 M 778 M 721 M 722 M 638 M 626 M 605 M 605 M 620 M 576 M 549 M 545 M 581 M 538 M 506 M 492 M 509 M 462 M 443 M 448 M 467 M 418 M 400 M 406 M 413 M 382 M 352 M 384 M 390 M 360 M 354 M 338 M 353 M 332 M 320 M 315 M 336 M 323 M 307 M 301 M 318 M 293 M - - -

Cost of Revenue

450 M 437 M 418 M 432 M 422 M 415 M 375 M 384 M 380 M 384 M 371 M 375 M 368 M 371 M 357 M 344 M 335 M 347 M 338 M 345 M 338 M 337 M 307 M 311 M 299 M 258 M 267 M 274 M 260 M 262 M 244 M - 240 M 248 M 235 M 234 M 218 M 216 M 204 M 202 M 202 M 206 M 190 M 182 M 182 M 181 M 167 M 170 M 170 M 172 M 158 M 165 M 153 M 155 M 148 M 150 M 145 M 151 M 148 M 148 M 142 M 144 M 138 M 139 M 127 M 132 M

Gross Profit

764 M 779 M 723 M 658 M 683 M 695 M 623 M 571 M 596 M 619 M 593 M 526 M 548 M 573 M 543 M 485 M 507 M 514 M 499 M 456 M 473 M 489 M 471 M 410 M 423 M 379 M 360 M 331 M 345 M 358 M 332 M 300 M 306 M 332 M 303 M 272 M 274 M 293 M 258 M 241 M 247 M 261 M 228 M 218 M 224 M 233 M 216 M 182 M 213 M 219 M 202 M 189 M 186 M 198 M 184 M 169 M 171 M 185 M 175 M 159 M 159 M 174 M 155 M 145 M 142 M 149 M

Operating Income

402 M 426 M 363 M 316 M 355 M 373 M 317 M 262 M 304 M 264 M 299 M 245 M 275 M 296 M 280 M 227 M 245 M 179 M 248 M 199 M 226 M 259 M 248 M 185 M 172 M 193 M 144 M 116 M 140 M 164 M 133 M 115 M 117 M 146 M 113 M 97.8 M 100 M 123 M 92.2 M 83.8 M 88.5 M 104 M 73.8 M 66.9 M 71.9 M 88.3 M 72.8 M 34.8 M 72.2 M 83.2 M 70 M 61.3 M 65.5 M 78.8 M 61.2 M 63.4 M 62.9 M 75.8 M 60.4 M 55.3 M 56.1 M 71.3 M 53.5 M 50.8 M 49.8 M 54.8 M

Interest Expense

- - - - - - - - - - 7.91 M 9.26 M 8.65 M 10.5 M 13.1 M 13.5 M 11 M 8.32 M 7 M 7.48 M 7.13 M 7.61 M 7.58 M 7.83 M 8.11 M 9.5 M 7.69 M 7.39 M 7.09 M 8.19 M 8.39 M - 8.45 M 8.46 M 9.27 M 9.72 M 9.76 M 9.16 M 8.59 M 7.76 M 7.79 M 8.2 M 8.3 M 7.93 M 7.75 M 7.26 M 6.3 M 5.4 M 4.29 M 2.96 M 2.77 M 1.91 M 1.46 M 1.18 M 835 K 856 K 873 K 926 K 1.19 M 1.11 M 928 K 782 K 728 K 674 K 687 K 689 K

EBITDA

402 M 504 M 400 M 316 M 391 M 373 M 351 M 262 M 338 M 264 M 329 M 174 M 304 M 324 M 309 M 158 M 273 M 207 M 275 M 134 M 252 M 285 M 273 M 123 M 197 M 217 M 168 M 59.6 M 162 M 186 M 154 M 115 M 180 M 166 M 134 M 45.2 M 121 M 143 M 113 M 35.3 M 108 M 124 M 92.3 M 26.1 M 90.2 M 105 M 89 M 991 K 87.7 M 97.9 M 83.4 M 29.9 M 79.3 M 92.6 M 74.7 M 34.7 M 75.7 M 88.8 M 73.1 M 28.6 M 68.1 M 83.2 M 65 M 50.8 M 61.3 M 77.5 M

Operating Expenses

362 M 354 M 360 M 343 M 329 M 322 M 307 M 309 M 292 M 355 M 294 M 281 M 273 M 277 M 263 M 258 M 262 M 335 M 250 M 257 M 247 M 230 M 223 M 224 M 251 M 186 M 215 M 216 M 205 M 194 M 198 M 185 M 188 M 187 M 190 M 175 M 174 M 170 M 166 M 157 M 158 M 156 M 154 M 151 M 152 M 144 M 143 M 147 M 141 M 135 M 132 M 127 M 120 M 119 M 123 M 106 M 108 M 109 M 114 M 104 M 103 M 103 M 101 M 94 M 92.4 M 94.4 M

General and Administrative Expenses

123 M 117 M 119 M 109 M 106 M 98.7 M 91.6 M 101 M 91.9 M 157 M 92 M 87 M 89 M 89.7 M 70.1 M 83 M 83.8 M 81.5 M 77.9 M 83.5 M 82.1 M 73.3 M 70.8 M 69.7 M 105 M 60.3 M 65.8 M 74.7 M 66.3 M 60 M 60.4 M - 64 M 61.1 M 60.9 M 55.3 M 57.2 M 55.5 M 52.9 M 50.8 M 52.6 M 54.3 M 49.3 M 48.8 M 46.2 M 44.9 M 42.6 M 45.3 M 45.7 M 41.8 M 41.1 M 41 M 38.7 M 38.9 M 41.6 M 31.8 M 35.3 M 34.3 M 36.2 M 31.2 M 32.5 M 33.1 M 32.6 M 29.9 M 30.7 M 33.1 M

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements IDEXX Laboratories IDXX
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting IDEXX Laboratories plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Diagnostics research industry

Issuer Price % 24h Market Cap Country
Pacific Biosciences of California Pacific Biosciences of California
PACB
$ 1.64 -7.1 % $ 492 M usaUSA
Neogen Corporation Neogen Corporation
NEOG
$ 10.45 -3.73 % $ 2.27 B usaUSA
Personalis Personalis
PSNL
$ 14.29 -2.96 % $ 1.28 B usaUSA
Quidel Corporation Quidel Corporation
QDEL
$ 8.31 -6.84 % $ 350 M usaUSA
Centogene N.V. Centogene N.V.
CNTG
- -6.23 % $ 30.6 M germanyGermany
Waters Corporation Waters Corporation
WAT
$ 438.11 -4.11 % $ 26.1 B usaUSA
Neuronetics Neuronetics
STIM
$ 1.24 -4.44 % $ 81.8 M usaUSA
Trinity Biotech plc Trinity Biotech plc
TRIB
$ 6.24 13.76 % $ 2.24 B irlandaIrlanda
Exagen Exagen
XGN
$ 3.59 -5.53 % $ 77.4 M usaUSA
Global Cord Blood Corporation Global Cord Blood Corporation
CO
- - $ 399 M chinaChina
Genetic Technologies Limited Genetic Technologies Limited
GENE
- - $ 7.1 B australiaAustralia
Genetron Holdings Limited Genetron Holdings Limited
GTH
- 0.12 % $ 80.1 M chinaChina
VolitionRx Limited VolitionRx Limited
VNRX
$ 0.16 -1.97 % $ 20.1 M singaporeSingapore
Aspira Women's Health Aspira Women's Health
AWH
- -6.19 % $ 10.5 M usaUSA
Check-Cap Ltd. Check-Cap Ltd.
CHEK
- - $ 9.42 M israelIsrael
Exact Sciences Corporation Exact Sciences Corporation
EXAS
- - $ 19.8 B usaUSA
National Research Corporation National Research Corporation
NRC
$ 25.18 0.76 % $ 564 M usaUSA
Twist Bioscience Corporation Twist Bioscience Corporation
TWST
$ 103.2 -7.54 % $ 6.46 B usaUSA
Organovo Holdings Organovo Holdings
ONVO
- -2.3 % $ 19.4 M usaUSA
OpGen OpGen
OPGN
- -16.95 % $ 1.54 M usaUSA
PerkinElmer PerkinElmer
PKI
- -0.91 % $ 14.7 B usaUSA
Soleno Therapeutics Soleno Therapeutics
SLNO
- - $ 2.69 B usaUSA
Enzo Biochem Enzo Biochem
ENZ
- -8.98 % $ 14.8 K usaUSA
Chembio Diagnostics Chembio Diagnostics
CEMI
- 0.22 % $ 16.8 M usaUSA
Renalytix AI plc Renalytix AI plc
RNLX
- 5.66 % $ 22.7 M britainBritain
Meridian Bioscience Meridian Bioscience
VIVO
- - $ 1.49 B usaUSA
Heska Corporation Heska Corporation
HSKA
- - $ 1.31 B usaUSA
Accelerate Diagnostics Accelerate Diagnostics
AXDX
- -61.36 % $ 2.46 M usaUSA
T2 Biosystems T2 Biosystems
TTOO
- -39.35 % $ 313 K usaUSA
Syneos Health Syneos Health
SYNH
- - $ 4.46 B usaUSA
Biocept Biocept
BIOC
- -13.05 % $ 7.29 M usaUSA
Invitae Corporation Invitae Corporation
NVTA
- - $ 21.2 M usaUSA
Quotient Limited Quotient Limited
QTNT
- -11.32 % $ 1.1 M schweizSchweiz
Brainsway Ltd. Brainsway Ltd.
BWAY
$ 8.53 -2.29 % $ 290 M israelIsrael
Burning Rock Biotech Limited Burning Rock Biotech Limited
BNR
$ 13.46 1.05 % $ 142 M chinaChina
Medpace Holdings Medpace Holdings
MEDP
$ 609.81 -3.81 % $ 17.6 B usaUSA
DermTech DermTech
DMTK
- -11.32 % $ 2.94 M usaUSA
Surmodics Surmodics
SRDX
- - $ 608 M usaUSA
RadNet RadNet
RDNT
$ 69.77 0.37 % $ 5.25 B usaUSA
Akumin Akumin
AKU
- -17.87 % $ 25.9 M canadaCanada
Psychemedics Corporation Psychemedics Corporation
PMD
- -1.84 % $ 15.3 M usaUSA
Motus GI Holdings Motus GI Holdings
MOTS
- -34.28 % $ 263 K israelIsrael
Biodesix Biodesix
BDSX
$ 7.55 -9.1 % $ 57 M usaUSA
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
- -20.0 % $ 1.06 M usaUSA
Agilent Technologies Agilent Technologies
A
$ 169.82 -3.21 % $ 48.2 B usaUSA
Charles River Laboratories International Charles River Laboratories International
CRL
$ 314.38 -4.13 % $ 15.6 B usaUSA
Quest Diagnostics Incorporated Quest Diagnostics Incorporated
DGX
$ 257.78 -0.4 % $ 28.6 B usaUSA
Danaher Corporation Danaher Corporation
DHR
$ 220.3 -3.19 % $ 157 B usaUSA
DexCom DexCom
DXCM
$ 79.02 -1.46 % $ 30.8 B usaUSA